Oncology Clinical Trials in Ypsilanti, MI
As of June 2026, 34 paid clinical trials are recruiting for Oncology in Ypsilanti, Michigan. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
34 clinical trials for Oncology
·Clear filters·↓ Download CSVUnderstanding Needs of Older Patients Prior to Starting Cancer Treatment
Prospective Study to Assess a Diagnostic Aid for Cancer
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Mobile Health for Adherence in Breast Cancer Patients
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A Study of ASP3082 in Adults With Advanced Solid Tumors
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
About research studies in Ypsilanti
Ypsilanti has approximately 138 recruiting research studies across a wide range of therapeutic areas. Michigan hosts University of Michigan Health, Henry Ford Health, and Corewell Health, running trials across oncology, neurology, and cardiology with a strong focus on precision medicine.
Top Research Study Locations in Ypsilanti
Researchers run research studies in Ypsilanti, MI at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Stage IV Lung Cancer AJCC v8, Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8 | 80 |
| Huron Gastroenterology PC | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma | 45 |
| Trinity Health Michigan Heart | Heart Failure, Acute Myocardial Infarction (AMI), Cardiovascular Risk | 5 |
| Forest Health Medical Center | Chronic Pain, Lumbar Spinal Stenosis, Pain | 3 |
| Michigan Heart | Hypertension, Hypertension, Essential, Hypertension, Systolic | 3 |
| 89bio Clinical Study Site | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | 2 |
| Huron Gastroenterology Associates, P.C. | Crohn's Disease, Ulcerative Colitis | 2 |
| Respiratory Medicine Research Institute of Michigan, PLC | Atopic Dermatitis, Eczema, Perennial Allergic Rhinitis (PAR) | 2 |
| Trinity Health | Atrial Fibrillation, HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer | 2 |
| Akero Clinical Study Site | MASH With Fibrosis, NASH With Fibrosis | 1 |
| Allergy & Immunology Associates of Ann Arbor | Dermatitis Atopic | 1 |
| Dawn Farm | Alcohol Use Disorder, Criminal Behavior, Health Risk Behaviors | 1 |
| Huron Gastro | Crohn's Disease, Ulcerative Colitis | 1 |
| Huron Gastroenterology | Cancer | 1 |
| Huron Gastroenterology Associates | Eosinophilic Esophagitis | 1 |
| Huron Gastroenterology Associates - Center for Digestive Care | Primary Biliary Cholangitis (PBC) | 1 |
| Investigative | Solid Tumors | 1 |
| Michigan Heart, PC | Heart Failure | 1 |
| Mirador Therapeutics Selected Site | Crohn's Disease, Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) | 1 |
| Research | Severe Asthma | 1 |
| Respiratory Medicine Research Institute of Michigan PLC | Chronic Spontaneous Urticaria | 1 |
| Saint Joseph Mercy Ann Arbor | Coronary Artery Disease | 1 |
| St. Joseph Mercy Health System | Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis | 1 |
| St. Joseph Mercy Hospital - Huron Gastroenterology Associates | Colitis, Ulcerative, Crohn Disease | 1 |
| Tenax Investigational Site | Pulmonary Hypertension Associated With HFpEF | 1 |
Active & Upcoming Studies in Ypsilanti (2026)
Recruiting trials in Ypsilanti grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (82 active studies)
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) · Phase 2 · National Cancer Institute (NCI)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · SWOG Cancer Research Network
Cardiovascular (19 active studies)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
- LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 · Phase 3 · Tenax Therapeutics, Inc.
Diabetes & metabolic (5 active studies)
Neurology & pain (2 active studies)
- RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain · Boston Scientific Corporation
- Patient Retrospective Outcomes (PRO) · Boston Scientific Corporation
Common conditions studied in Ypsilanti
- Heart Failure (8 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Stage IV Lung Cancer AJCC v8 (7 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
- Acute Myeloid Leukemia (6 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Anatomic Stage IV Breast Cancer AJCC v8 (4 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Malignant Solid Neoplasm (4 active studies). Recruiting Malignant Solid Neoplasm studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Ypsilanti
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- NRG Oncology
- ECOG-ACRIN Cancer Research Group
Local regulations and guidelines
Clinical trials in Michigan are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Michigan research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Ypsilanti. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Ypsilanti
Hipa.ai aggregates every recruiting study in Ypsilanti from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Ypsilanti?
There are approximately 138 recruiting clinical trials in Ypsilanti, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Ypsilanti pay participants?
Most recruiting trials in Ypsilanti compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Ypsilanti?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Ypsilanti?
The most common conditions under active study in Ypsilanti include Heart Failure (8), Stage IV Lung Cancer AJCC v8 (7), Acute Myeloid Leukemia (6), Anatomic Stage II Breast Cancer AJCC v8 (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Ypsilanti?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Ypsilanti on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Ypsilanti?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Ypsilanti?
Recruiting research sites in Ypsilanti include Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Huron Gastroenterology PC, Trinity Health Michigan Heart, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Ypsilanti right now?
The largest active categories in Ypsilanti are Cancer & tumors (82), Cardiovascular (19), Diabetes & metabolic (5). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.